Does the media refer more to TGTX or GENB?

In the previous week, TG Therapeutics had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 7 mentions for TG Therapeutics and 4 mentions for Generate Biomedicines. TG Therapeutics' average media sentiment score of 0.71 beat Generate Biomedicines' score of 0.07 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SYRE or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Generate Biomedicines N/A N/A N/A

Does the media prefer SYRE or GENB?

In the previous week, Generate Biomedicines had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 4 mentions for Generate Biomedicines and 3 mentions for Spyre Therapeutics. Generate Biomedicines' average media sentiment score of 0.07 beat Spyre Therapeutics' score of 0.05 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IONS or GENB?

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for Ionis Pharmaceuticals and 4 mentions for Generate Biomedicines. Ionis Pharmaceuticals' average media sentiment score of 0.55 beat Generate Biomedicines' score of 0.07 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALKS or GENB?

In the previous week, Alkermes had 22 more articles in the media than Generate Biomedicines. MarketBeat recorded 26 mentions for Alkermes and 4 mentions for Generate Biomedicines. Alkermes' average media sentiment score of 0.67 beat Generate Biomedicines' score of 0.07 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 9 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Generate Biomedicines N/A N/A N/A

Does the media refer more to IMVT or GENB?

In the previous week, Immunovant had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 10 mentions for Immunovant and 4 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.07 beat Immunovant's score of 0.01 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Generate Biomedicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Generate Biomedicines (GENB) Competitors

$16.52 -0.94 (-5.38%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$16.64 +0.12 (+0.70%)

As of 06:48 AM Eastern

Compare

GENB vs. TGTX, SYRE, IONS, ALKS, and IMVT

Should you buy Generate Biomedicines stock or one of its competitors? Generate Biomedicines's main competitors and comparable companies include TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Generate Biomedicines compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

TG Therapeutics has a net margin of 55.22% compared to Generate Biomedicines' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Generate Biomedicines	N/A	N/A	N/A

TG Therapeutics currently has a consensus price target of $63.00, indicating a potential upside of 12.50%. Generate Biomedicines has a consensus price target of $26.40, indicating a potential upside of 59.81%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, TG Therapeutics had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 7 mentions for TG Therapeutics and 4 mentions for Generate Biomedicines. TG Therapeutics' average media sentiment score of 0.71 beat Generate Biomedicines' score of 0.07 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.91	$447.18M	$2.74	20.44
Generate Biomedicines	$31.89M	66.49	-$203.15M	-$1.59	N/A

Summary

TG Therapeutics beats Generate Biomedicines on 11 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Spyre Therapeutics presently has a consensus target price of $109.69, indicating a potential upside of 24.41%. Generate Biomedicines has a consensus target price of $26.40, indicating a potential upside of 59.81%. Given Generate Biomedicines' higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Generate Biomedicines	N/A	N/A	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spyre Therapeutics has higher earnings, but lower revenue than Generate Biomedicines. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Generate Biomedicines	$31.89M	66.49	-$203.15M	-$1.59	N/A

In the previous week, Generate Biomedicines had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 4 mentions for Generate Biomedicines and 3 mentions for Spyre Therapeutics. Generate Biomedicines' average media sentiment score of 0.07 beat Spyre Therapeutics' score of 0.05 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Generate Biomedicines beats Spyre Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Generate Biomedicines compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Ionis Pharmaceuticals presently has a consensus price target of $90.50, indicating a potential upside of 106.01%. Generate Biomedicines has a consensus price target of $26.40, indicating a potential upside of 59.81%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Generate Biomedicines has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.73	-$381.39M	-$3.46	N/A
Generate Biomedicines	$31.89M	66.49	-$203.15M	-$1.59	N/A

Generate Biomedicines has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Generate Biomedicines' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Generate Biomedicines	N/A	N/A	N/A

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than Generate Biomedicines. MarketBeat recorded 13 mentions for Ionis Pharmaceuticals and 4 mentions for Generate Biomedicines. Ionis Pharmaceuticals' average media sentiment score of 0.55 beat Generate Biomedicines' score of 0.07 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ionis Pharmaceuticals beats Generate Biomedicines on 8 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Alkermes has a net margin of 3.96% compared to Generate Biomedicines' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Generate Biomedicines	N/A	N/A	N/A

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alkermes had 22 more articles in the media than Generate Biomedicines. MarketBeat recorded 26 mentions for Alkermes and 4 mentions for Generate Biomedicines. Alkermes' average media sentiment score of 0.67 beat Generate Biomedicines' score of 0.07 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	9 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes currently has a consensus price target of $54.75, suggesting a potential upside of 29.95%. Generate Biomedicines has a consensus price target of $26.40, suggesting a potential upside of 59.81%. Given Generate Biomedicines' higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Alkermes has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.79	$241.66M	$0.38	110.87
Generate Biomedicines	$31.89M	66.49	-$203.15M	-$1.59	N/A

Summary

Alkermes beats Generate Biomedicines on 14 of the 16 factors compared between the two stocks.

How does Generate Biomedicines compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Generate Biomedicines	$31.89M	66.49	-$203.15M	-$1.59	N/A

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 27.39%. Generate Biomedicines has a consensus target price of $26.40, suggesting a potential upside of 59.81%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Immunovant had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 10 mentions for Immunovant and 4 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.07 beat Immunovant's score of 0.01 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Generate Biomedicines beats Immunovant on 9 of the 13 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.24B	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-10.39	13.88	274.06	25.69
Price / Sales	66.49	1,343.72	637.81	78.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	N/A	15.21	10.40	6.32
Net Income	-$203.15M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-3.50%	-1.72%	-0.69%	0.17%
1 Month Performance	-6.77%	-6.17%	-3.18%	-3.27%
1 Year Performance	N/A	30.66%	15.13%	5.58%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	3.0501 of 5 stars	$16.52 -5.4%	$26.40 +59.8%	N/A	$2.24B	$31.89M	N/A	312
TGTX TG Therapeutics	3.5368 of 5 stars	$53.04 -1.8%	$63.00 +18.8%	+57.4%	$8.12B	$616.29M	19.36	399	Analyst Upgrade
SYRE Spyre Therapeutics	2.432 of 5 stars	$90.95 +0.2%	$109.69 +20.6%	+450.4%	$8.00B	N/A	N/A	112
IONS Ionis Pharmaceuticals	3.1303 of 5 stars	$47.25 -8.1%	$91.25 +93.1%	-29.8%	$7.85B	$944M	N/A	1,402	Trending News Analyst Forecast High Trading Volume
ALKS Alkermes	3.525 of 5 stars	$46.03 +0.4%	$54.56 +18.5%	+51.8%	$7.72B	$1.67B	121.13	2,050	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. TGTX, SYRE, IONS, ALKS, and IMVT

How does Generate Biomedicines compare to TG Therapeutics?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Summary

How does Generate Biomedicines compare to Ionis Pharmaceuticals?

Summary

How does Generate Biomedicines compare to Alkermes?

Summary

How does Generate Biomedicines compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. TGTX, SYRE, IONS, ALKS, and IMVT

How does Generate Biomedicines compare to TG Therapeutics?

Is TGTX or GENB more profitable?

Do analysts recommend TGTX or GENB?

Does the media refer more to TGTX or GENB?

Do insiders and institutionals have more ownership in TGTX or GENB?

Which has preferable valuation & earnings, TGTX or GENB?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Do analysts recommend SYRE or GENB?

Is SYRE or GENB more profitable?

Do institutionals and insiders have more ownership in SYRE or GENB?

Which has stronger earnings and valuation, SYRE or GENB?

Does the media prefer SYRE or GENB?

Summary

How does Generate Biomedicines compare to Ionis Pharmaceuticals?

Do analysts rate IONS or GENB?

Which has stronger valuation & earnings, IONS or GENB?

Is IONS or GENB more profitable?

Do institutionals & insiders believe in IONS or GENB?

Does the media refer more to IONS or GENB?

Summary

How does Generate Biomedicines compare to Alkermes?

Is ALKS or GENB more profitable?

Do institutionals and insiders hold more shares of ALKS or GENB?

Does the media favor ALKS or GENB?

Do analysts prefer ALKS or GENB?

Which has higher valuation and earnings, ALKS or GENB?

Summary

How does Generate Biomedicines compare to Immunovant?

Do institutionals & insiders hold more shares of IMVT or GENB?

Is IMVT or GENB more profitable?

Which has higher earnings & valuation, IMVT or GENB?

Do analysts prefer IMVT or GENB?

Does the media refer more to IMVT or GENB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools